Can a targeted drug boost hormone therapy for prostate cancer before surgery?
NCT ID NCT01409200
First seen Jan 04, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This phase 2 trial tested whether adding the drug axitinib to standard hormone therapy before surgery helps control prostate cancer that has spread to nearby lymph nodes. 73 men with previously untreated prostate cancer received either hormone therapy alone or hormone therapy plus axitinib before having their prostate removed. The main goal was to see how long it took for the cancer to show signs of returning after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PROSTATE ADENOCARCINOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axitinib (a drug that blocks tumor blood vessel growth) and antiandrogen therapy (hormone therapy that lowers male hormones)
What this could lead to
If successful, this approach could help control prostate cancer that has spread to lymph nodes, potentially delaying its return after surgery.
What could go wrong
This is a small, early-phase trial (73 people) that is already completed, so results may not be definitive. Adding axitinib also carries risks like high blood pressure and fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.